PDS Biotechnology Croissance future
Future contrôle des critères 0/6
PDS Biotechnology devrait augmenter ses bénéfices et ses revenus de 44.9% et de 66% par an respectivement, tandis que le BPA devrait croître de croître de 48% par an.
Informations clés
44.9%
Taux de croissance des bénéfices
48.00%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.5% |
| Taux de croissance des recettes | 66.0% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 13 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapy treatments for HPV16 positive cancers and other solid tumors. What are the underlying business or industry changes driving this perspective?
Regulatory And Financing Risks Around HPV Cancer Program Will Eventually Reward Patience
Catalysts About PDS Biotechnology PDS Biotechnology is a clinical stage company developing immunotherapy treatments for HPV16 positive cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?
HPV Positive Cancer Tailwinds And Trial Design Shifts Will Support Long Term Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapies for HPV16-positive head and neck cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Summary PDS Biotech is a clinical-stage company focused on developing immunotherapy-based approaches for cancer, with a focus on virus-driven tumors. Their main pipeline project is PDS0101, an immunotherapy targeting the p16 protein found in HPV16-infected cells in head and neck cancer. PDSB has shown promising clinical data, with a 74% 2-year overall survival rate in a phase 2 study, but their cash position is a concern. Read the full article on Seeking AlphaPDS Biotech jumps 13% as FDA clears further development of lead asset
PDS Biotechnology (NASDAQ:PDSB), a biopharma focused on cancer immunotherapies, added 13% pre-market Monday after the company announced that a recent End-of-Phase 2 meeting with the FDA brought clarity to the late-stage development of its lead asset PDS0101. At the meeting, PDSB has submitted interim data to indicate the potential of PDS0101 against a particular form of head and neck squamous cell carcinoma (HNSCC) in combination with Merck's (MRK) anti-PD-1 therapy, Keytruda. "The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule," Chief Executive Frank Bedu-Addo remarked. The FDA has issued Fast Track designation to PDS0101/ Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer.PDS Biotechnology files for $150 mixed shelf offering
PDS Biotechnology Corp. (NASDAQ:PDSB) has filed for a $150 mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for development and commercialization of product candidates and general corporate purposes. Separately, PDS Biotechnology (PDSB) said it entered into a debt financing agreement led by Horizon Technology Finance Corporation (HRZN) for up to $35M. Seeking Alpha's Quant Rating views PDS Biotechnology (PDSB) as a hold.PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
PDS Biotechnology (NASDAQ:PDSB) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda be continued without changes. The decision of the independent Data Monitoring Committee (DMC) was based on safety data from the study which is designed to study PDS0101 and Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer. The DMC analysis of 43 patients indicated that there were no drug discontinuations related to toxicity or treatment related Grade 3 or greater adverse events, according to the company. In May, PDS Biotech (PDSB) announced that U.K. regulators accepted its application seeking to conduct the VERSATILE-002 trial in that country.PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or metastatic head and neck cancer patients. Proof of concept for PDS Biotechnology's Versamune T-cell activating technology platform was established. PDS Biotechnology had $58.9 million in cash as of March 31, 2022; enough cash to fund its operations into 2024.PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
PDS0101 could become the first line therapy in HPV-16 associated cancers (40,500 cases/year in the U.S. or $6 billion/year revenue opportunity). The company has an enterprise value of just $125M. The stock has near-term catalysts this year and is at a good buy level.Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 2 | -35 | -46 | N/A | 2 |
| 12/31/2027 | N/A | -35 | -39 | N/A | 2 |
| 12/31/2026 | N/A | -31 | -30 | N/A | 2 |
| 3/31/2026 | N/A | -33 | N/A | N/A | N/A |
| 12/31/2025 | N/A | -34 | -28 | -28 | N/A |
| 9/30/2025 | N/A | -35 | -32 | -32 | N/A |
| 6/30/2025 | N/A | -37 | -34 | -34 | N/A |
| 3/31/2025 | N/A | -35 | -34 | -34 | N/A |
| 12/31/2024 | N/A | -38 | -35 | -35 | N/A |
| 9/30/2024 | N/A | -41 | -35 | -35 | N/A |
| 6/30/2024 | N/A | -41 | -34 | -34 | N/A |
| 3/31/2024 | N/A | -44 | -30 | -30 | N/A |
| 12/31/2023 | N/A | -43 | -34 | -34 | N/A |
| 9/30/2023 | N/A | -51 | -33 | -33 | N/A |
| 6/30/2023 | N/A | -48 | -31 | -31 | N/A |
| 3/31/2023 | N/A | -42 | -33 | -33 | N/A |
| 12/31/2022 | N/A | -41 | -26 | -26 | N/A |
| 9/30/2022 | N/A | -28 | -23 | -23 | N/A |
| 6/30/2022 | N/A | -28 | -22 | -22 | N/A |
| 3/31/2022 | N/A | -22 | -15 | -15 | N/A |
| 12/31/2021 | N/A | -17 | -12 | -12 | N/A |
| 9/30/2021 | N/A | -15 | -13 | -13 | N/A |
| 6/30/2021 | N/A | -12 | -9 | -9 | N/A |
| 3/31/2021 | N/A | -14 | -14 | -14 | N/A |
| 12/31/2020 | N/A | -15 | -13 | -13 | N/A |
| 9/30/2020 | N/A | -15 | -14 | -14 | N/A |
| 6/30/2020 | N/A | -17 | -17 | -17 | N/A |
| 3/31/2020 | N/A | -18 | -18 | -18 | N/A |
| 12/31/2019 | N/A | -7 | N/A | -18 | N/A |
| 9/30/2019 | N/A | -5 | N/A | -13 | N/A |
| 6/30/2019 | N/A | 0 | N/A | -9 | N/A |
| 3/31/2019 | N/A | 4 | N/A | -5 | N/A |
| 12/31/2018 | N/A | -4 | N/A | -2 | N/A |
| 9/30/2018 | N/A | -2 | N/A | -2 | N/A |
| 12/31/2017 | N/A | -3 | N/A | -3 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: PDSB devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: PDSB devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: PDSB devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: PDSB ne devrait pas générer de revenus l'année prochaine.
Croissance élevée des revenus: PDSB ne devrait pas générer de revenus l'année prochaine.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de PDSB devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 11:07 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
PDS Biotechnology Corporation est couverte par 5 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |